alphaveGLAXO₹2,858.00

Glaxosmithkline Pharmaceuticals Ltd.

₹ CrorePeersPFIZER ABBOTINDIA MEDANTA ANTHEM AJANTPHARM IPCALAB GLENMARK BIOCONMcap ₹48,417 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Non-current Assets
+ Property, Plant & Equipment	296.8	269.5	273.5	273.5
+ Capital Work-in-Progress	13.9	14.3	32.9	32.9
+ Investment Property	0.9	0.8	0.7	0.7
+ Other Intangibles	23.6	13.3	6.6	6.6
+ Investments (Equity Method)	0.0	0.0	0.9	0.9
+ Other Non-current Financial Assets	10.2	11.5	13.4	13.4
Non-current Financial Assets	10.2	11.5	13.4	13.4
+ Deferred Tax Assets	146.3	140.9	133.9	133.9
+ Other Non-current Assets	52.8	51.9	77.3	77.3
Total Non-current Assets	544.6	502.2	539.2	539.2
Current Assets
+ Inventories	525.1	481.7	457.6	457.6
+ Current Investments	813.2	1,118.3	1,391.0	1,391.0
+ Trade Receivables	222.1	292.6	273.1	273.1
+ Cash & Cash Equivalents	64.2	538.9	1,102.1	1,102.1
+ Other Bank Balances	999.1	864.7	289.0	289.0
+ Other Current Financial Assets	130.1	70.8	39.2	39.2
Current Financial Assets	2,228.6	2,885.1	3,094.3	3,094.3
+ Other Current Assets	44.7	43.1	54.4	54.4
Total Current Assets	3,012.1	3,605.9	3,784.7	3,784.7
Total Assets	3,556.6	4,108.1	4,323.9	4,323.9
Equity
+ Equity Share Capital	169.4	169.4	169.4	169.4
+ Other Equity / Reserves	1,608.2	1,781.9	2,098.0	2,098.0
Equity — Owners of Parent	1,777.6	1,951.3	2,267.4	2,267.4
+ Minority Interest	0.0	0.0	17.3	17.3
Total Equity	1,777.6	1,951.3	2,284.7	2,284.7
Liabilities
+ Other Non-current Financial Liab	6.6	2.5	—	—
Non-current Financial Liabilities	6.6	2.5	0.0	0.0
+ Provisions — Non-current	247.5	249.1	260.1	260.1
Non-current Liabilities	254.0	251.6	260.1	260.1
+ Trade Payables	625.4	708.3	570.2	570.2
+ Other Current Financial Liab	154.3	184.5	125.6	125.6
Current Financial Liabilities	779.7	892.7	695.8	695.8
+ Provisions — Current	393.5	416.4	419.2	419.2
+ Current Tax Liabilities	298.6	524.5	546.0	546.0
+ Other Current Liabilities	53.1	71.5	118.2	118.2
Current Liabilities	1,525.0	1,905.2	1,779.1	1,779.1
Total Liabilities	1,779.0	2,156.8	2,039.2	2,039.2
Total Equity & Liabilities	3,556.6	4,108.1	4,323.9	4,323.9
Assets — additional as-filed lines
+ Current Tax Assets	213.6	196.0	178.5	178.5
Trade Payables — MSME split
+ Dues to Micro & Small — Current	—	8.5	6.7	6.7
+ Dues to Other Creditors — Current	—	699.7	563.5	563.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.